Case Reports of DRESS Syndrome and Symptoms Consistent with DRESS Syndrome Following Treatment with Recently Marketed Monoclonal Antibodies
المؤلفون المشاركون
Di Palma-Grisi, James C.
Vijayagopal, Kesav
Muslimani, Muhammad A.
المصدر
العدد
المجلد 2019، العدد 2019 (31 ديسمبر/كانون الأول 2019)، ص ص. 1-6، 6ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2019-06-09
دولة النشر
مصر
عدد الصفحات
6
التخصصات الرئيسية
الملخص EN
Background.
Monoclonal antibodies constitute a potent and broadly tolerable drug class, representing for some conditions the first newly approved treatment in years.
As such, many are afforded “fast-track” or “breakthrough therapy” designations by the U.S.
Food and Drug Administration, leading to provisional approval before Phase III clinical trials are reported.
Although these drugs are usually safe, some patients experience life-threatening complications—myositis and encephalitis have led to permanent or temporary recalls.
Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a hypersensitivity condition easily missed due to its long incubation period and nonspecific presentation.
This minireview is primarily intended as an abbreviated guide for practitioners who may be using these powerful treatments.
Methodology.
We searched PubMed using a string of symptoms consistent with DRESS syndrome and monoclonal antibodies approved by the FDA since 2015.
Then, we excluded studies reporting dermatological complications of reactivation of nonherpetic infection, immunodeficiency-related infection, or reactions to the injection site or infusion.
We searched for and accessed prior reviews and background studies via PubMed, Mendeley, and Google Scholar.
Results.
Two cases of DRESS syndrome were identified in the literature, both the result of treatment with daclizumab.
There was one additional case of encephalitis without cutaneous symptoms caused by daclizumab.
Drug-induced hypersensitivity dermatitis was reported following treatment with nivolumab and two cases of combination treatment with ipilimumab and either nivolumab or durvalumab produced maculopapular rash and bullae in the first patient and lichenoid dermatitis and blisters in the second patient.
Conclusions.
Daclizumab was the only recently approved monoclonal antibody associated with DRESS syndrome as such.
Limitations in the diagnostic reliability of DRESS syndrome as a clinical entity and the lack of negative clinical trial reporting suggest enhanced vigilance on the part of clinicians and regulators may be warranted.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Di Palma-Grisi, James C.& Vijayagopal, Kesav& Muslimani, Muhammad A.. 2019. Case Reports of DRESS Syndrome and Symptoms Consistent with DRESS Syndrome Following Treatment with Recently Marketed Monoclonal Antibodies. Autoimmune Diseases،Vol. 2019, no. 2019, pp.1-6.
https://search.emarefa.net/detail/BIM-1117934
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Di Palma-Grisi, James C.…[et al.]. Case Reports of DRESS Syndrome and Symptoms Consistent with DRESS Syndrome Following Treatment with Recently Marketed Monoclonal Antibodies. Autoimmune Diseases No. 2019 (2019), pp.1-6.
https://search.emarefa.net/detail/BIM-1117934
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Di Palma-Grisi, James C.& Vijayagopal, Kesav& Muslimani, Muhammad A.. Case Reports of DRESS Syndrome and Symptoms Consistent with DRESS Syndrome Following Treatment with Recently Marketed Monoclonal Antibodies. Autoimmune Diseases. 2019. Vol. 2019, no. 2019, pp.1-6.
https://search.emarefa.net/detail/BIM-1117934
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1117934
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر